283.59MMarket Cap-3036P/E (TTM)
5.290High4.920Low931.18KVolume4.950Open4.970Pre Close4.73MTurnover2.26%Turnover RatioLossP/E (Static)56.27MShares7.66052wk High2.72P/B207.95MFloat Cap1.62052wk Low--Dividend TTM41.26MShs Float46.250Historical High--Div YieldTTM7.45%Amplitude1.180Historical Low5.080Avg Price1Lot Size
Black Diamond Therapeutics Stock Forum
NEWS
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGF...
$Black Diamond Therapeutics(BDTX.US)$
$NWTN Inc(NWTN.US)$
$LiveWire Group(LVWR.US)$
No comment yet